Dan

BlueSphere Bio Presents Data Demonstrating the Potential of Lead Product Candidate at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

PITTSBURGH, Nov. 10, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the presentation of data supporting the potential of its first and lead product candidate, BSB-1001, at the 37th Society for …

BlueSphere Bio Presents Data Demonstrating the Potential of Lead Product Candidate at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting Read More »

BlueSphere Bio Data to be Presented at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

PITTSBURGH, PA, November 03, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present data in a poster at the 37th Society …

BlueSphere Bio Data to be Presented at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting Read More »

BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer

Industry veteran brings nearly 20 years of broad leadership experience in biopharma PITTSBURGH, PA, October 04, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, announced the appointment of Keir Loiacono, Esq. to Chief Executive …

BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer Read More »

BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit

Parallel processing using TCXpress™ and iTCXpress™ platforms significantly increases throughput, reduces the cost and shortens the timing of identifying novel TCRs PITTSBURGH, Sept. 26, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today …

BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit Read More »

BlueSphere Bio to Present at the 7th Annual CAR-TCR Summit

PITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the company will present a poster, at the 7th Annual CAR-TCR Summit, being held in Boston, MA from September 19 – …

BlueSphere Bio to Present at the 7th Annual CAR-TCR Summit Read More »